ArticleAdvanced pharmaceutical bulletin2023
A Quantitative Structure-Activity Relationship for Human Plasma Protein Binding: Prediction, Validation and Applicability Domain.
Article in Advanced pharmaceutical bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- In Silico ADME Methods Used in the Evaluation of Natural Products.Pharmaceutics · 2025Review
- Leveraging machine learning models in evaluating ADMET properties for drug discovery and development.ADMET & DMPK · 2025Review
- H-Type Indices With Applications in Chemometrics: h-Accuracy Index for Evaluating and Comparing Errors in Analytical Chemistry.Journal of analytical methods in chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to develop a robust and externally predictive in silico QSAR-neural network model for predicting plasma protein binding of drugs. This model aims to enhance drug discovery processes by reducing the need for chemical synthesis and extensive laboratory testing. Methods: A dataset of 277 drugs was used to develop the QSAR-neural network model. The model was constructed using a Filter method to select 55 molecular descriptors. The validation set's external accuracy was assessed through the predictive squared correlation coefficient Q2 and the root mean squared error (RMSE). Results: The developed QSAR-neural network model demonstrated robustness and good applicability domain. The external accuracy of the validation set was high, with a predictive squared correlation coefficient Q2 of 0.966 and a root mean squared error (RMSE) of 0.063. Comparatively, this model outperformed previously published models in the literature. Conclusion: The study successfully developed an advanced QSAR-neural network model capable of predicting plasma protein binding in human plasma for a diverse set of 277 drugs. This model's accuracy and robustness make it a valuable tool in drug discovery, potentially reducing the need for resource-intensive chemical synthesis and laboratory testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.